Good
Partially Aligned
Patient Risk:
Moderate
Summary
Most key label-supported points (indication for extended adjuvant after trastuzumab, diarrhea severity/dehydration/electrolytes guidance, hepatotoxicity, HER2/EGFR targeting, and common diarrhea-related adverse effects) are consistent with the provided prescribing information excerpts. However, some claims are not directly supported by the supplied label text or are overstated/incorrectly framed (e.g., post-market surveillance content, blanket statement about blocking growth signaling, liver toxicity framing beyond hepatotoxicity, and that approval date is FDA approval July 21, 2017 which is not present in the provided excerpts).
Category Scores
Accurate Statements
FDA approval of neratinib was for the extended adjuvant treatment of adult patients with a history of early-stage HER2-positive breast cancer.
Label excerpt 1.1: “indicated for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer, to follow adjuvant trastuzumab based therapy.”
Neratinib (Nerlynx) is approved for extended adjuvant treatment in patients with early-stage HER2-positive breast cancer who have previously undergone surgery and a defined course of adjuvant therapy.
Supported in part by label excerpt 1.1 regarding adult early-stage HER2+ extended adjuvant following adjuvant trastuzumab. (The supplied excerpts do not mention surgery or “defined course of adjuvant therapy” details.)
Extended adjuvant treatment with neratinib aims to reduce the risk of invasive breast cancer recurrence.
Partially supported by label excerpt 1.1 describing indication for extended adjuvant treatment (explicit recurrence-risk language is not shown in provided excerpts).
Neratinib is a tyrosine kinase inhibitor.
Not present in provided excerpts; cannot be confirmed against supplied text.
Neratinib targets the HER2 and EGFR pathways.
Not present in provided excerpts; cannot be confirmed against supplied text.
The most common side effects of neratinib include diarrhea, nausea, abdominal pain, fatigue, rash, stomatitis, and decreased appetite.
Label excerpt provided includes diarrhea rates and mentions diarrhea as a key adverse reaction, but the provided excerpts do not list a full “most common” adverse-reaction list including these specific items.
Severe diarrhea is a significant concern with neratinib.
Label excerpt 5.1: “Severe diarrhea and sequelae, such as dehydration, hypotension, and renal failure occurred…” and diarrhea severity rates.
Severe diarrhea from neratinib can lead to dehydration and electrolyte imbalances.
Supported for dehydration: label excerpt 5.1 includes dehydration; label excerpt 2.1/5.1 indicates manage with “fluids and electrolytes as clinically indicated.”
Liver toxicity is a potential risk of neratinib.
Label excerpt 5.2: “associated with hepatotoxicity characterized by increased liver enzymes.”
Exacerbation of pre-existing conditions is a potential risk of neratinib.
Not present in provided excerpts; cannot be confirmed.
Following FDA approval, neratinib is subject to post-market surveillance.
Not present in provided excerpts; cannot be confirmed.
Unsupported Statements
Neratinib received FDA approval on July 21, 2017.
FDA approval date is not present in the supplied prescribing-information excerpts.
Neratinib is a tyrosine kinase inhibitor.
Mechanism class (tyrosine kinase inhibitor) is not present in the supplied label excerpts.
Neratinib targets the HER2 and EGFR pathways.
HER2/EGFR pathway targeting is not present in the supplied label excerpts.
By inhibiting HER2 and EGFR signaling, neratinib blocks signaling that can drive the growth of HER2-positive cancer cells.
Label excerpts provided do not describe this mechanistic claim.
The most common side effects of neratinib include diarrhea, nausea, abdominal pain, fatigue, rash, stomatitis, and decreased appetite.
Provided excerpts only explicitly discuss diarrhea and do not provide a “most common” list containing these specific adverse reactions.
Exacerbation of pre-existing conditions is a potential risk of neratinib.
Not present in provided label excerpts.
Following FDA approval, neratinib is subject to post-market surveillance.
Not present in provided label excerpts.
Post-market surveillance for neratinib includes monitoring for adverse events and ongoing clinical trials.
Not present in provided label excerpts.
The post-market monitoring for neratinib aims to further understand its long-term efficacy and safety profile.
Not present in provided label excerpts.
Neratinib (Nerlynx) is approved for extended adjuvant treatment in patients with early-stage HER2-positive breast cancer who have previously undergone surgery and a defined course of adjuvant therapy.
The supplied indication excerpt specifies following adjuvant trastuzumab, but does not mention surgery or the described phrasing about “defined course of adjuvant therapy.”
Extended adjuvant treatment with neratinib aims to reduce the risk of invasive breast cancer recurrence.
The supplied indication excerpt does not explicitly state recurrence-risk reduction wording.
Contradictions
Low
AI Statement
By inhibiting HER2 and EGFR signaling, neratinib blocks signaling that can drive the growth of HER2-positive cancer cells.
Label Reference
No contradiction can be established because the provided excerpts do not include mechanistic statements; therefore classification as contradiction is not supported by provided text.
Important Omissions
Exact extended adjuvant dosing regimen (240 mg once daily with food, continuously until recurrence or up to one year).
Importance:
Moderate
Requirement for antidiarrheal prophylaxis (loperamide with first dose and during first 56 days) and titration goals (1–2 bowel movements/day; dose guidance).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several safety-relevant claims are consistent with the supplied excerpts (severe diarrhea with dehydration; hepatotoxicity; electrolyte management). However, multiple statements are unsupported by the provided label text (e.g., post-market surveillance, mechanism class/pathway, 'exacerbation of pre-existing conditions'), and key label-driven administration/safety management details (dose, prophylaxis specifics) were omitted, which could reduce label fidelity.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple claims are not supported by the supplied prescribing-information excerpts (FDA approval date, mechanism/pathway statements, full “most common” adverse-event list, and post-market surveillance description). Additionally, important dosage/prophylaxis details from the label were omitted.
Suggested Improvement
Limit claims to those directly reflected in the provided label excerpts (indication following adjuvant trastuzumab; diarrhea management/prophylaxis; hepatotoxicity monitoring). Avoid unsourced statements about approval date, mechanism details (tyrosine kinase/EGFR), post-market surveillance, and unsupported adverse-event lists; include the label’s specific extended-adjuvant dosing and loperamide prophylaxis/titration instructions.